Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (NASDAQ: VKTX) announced promising results from its Phase 1 clinical trial for VK2735, a dual GLP-1/GIP receptor agonist aimed at treating metabolic disorders. The trial demonstrated a placebo-adjusted mean weight loss of 6.0% and a total weight loss of 7.8% from baseline over 28 days. VK2735 was found to be safe and well-tolerated, with the majority of adverse events being mild to moderate. A Phase 2 trial targeting obesity is slated for mid-2023, with further dose escalation planned based on these results.
Viking Therapeutics (NASDAQ: VKTX) announced its participation in two investor conferences on March 7, 2023. Brian Lian, Ph.D., CEO, will engage in a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, at 2:30 p.m. PT on March 13. Additionally, Dr. Lian will present at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023, at 7:40 a.m. PT on March 14. A live webcast of the Oppenheimer presentation will be available on the Viking website. Viking focuses on developing therapies for metabolic and endocrine disorders, with three compounds in clinical trials, including VK2809 for NASH and VK2735 for metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) announced its financial results for Q4 2022, reporting a net loss of $19.6 million or $0.26 per share, up from $12.4 million or $0.16 per share in Q4 2021. For the full year, its net loss was $68.9 million, compared to $55.0 million in 2021. The company is advancing its clinical pipeline, with enrollment completed in the Phase 2b VOYAGE trial for VK2809 targeting NASH and fibrosis, data expected in Q2 2023. Viking holds $155 million in cash, providing a solid financial foundation to pursue its clinical milestones and upcoming data releases for various programs, including VK2735 and VK0214.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced that CEO Brian Lian, Ph.D., will present at the SVB Securities Global Biopharma Conference from February 13-16, 2023. The presentation is scheduled for February 15 at 2:20 p.m. Eastern time and will be conducted virtually. Viking focuses on therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809 for non-alcoholic steatohepatitis (NASH) and VK2735 for various metabolic disorders. The company holds exclusive rights to five therapeutic programs developed from licensed small molecules.
Viking Therapeutics (NASDAQ: VKTX) will announce its fourth quarter and year-end 2022 financial results on February 8, 2023, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. The company focuses on developing therapies for metabolic and endocrine disorders and is currently running clinical trials for its compounds VK2809, VK2735, and VK0214. VK2809 is in a Phase 2b study for treating NASH and fibrosis, showing promising results in earlier trials. Interested parties can participate in the call by dialing specified numbers or can access the webcast on Viking's website.
Viking Therapeutics (NASDAQ: VKTX) announced the completion of patient enrollment in its Phase 2b clinical trial for VK2809, a novel treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). This double-blind, placebo-controlled trial targets a primary endpoint evaluating liver fat content changes at 12 weeks. The study represents a significant advancement in developing therapies for NASH. Viking previously achieved promising results in a Phase 2a trial, demonstrating reductions in liver fat and plasma lipids. Data for the primary endpoint is expected in the first half of 2023.
Viking Therapeutics, Inc. (VKTX) announced that CEO Brian Lian, Ph.D., will present at the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. The presentation is scheduled for 3:35 p.m. Eastern on November 15, and will include a live webcast available on their website. Viking focuses on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for non-alcoholic steatohepatitis and VK2735 for various metabolic disorders.
Viking Therapeutics (VKTX) announced its Q3 2022 financial results, reporting a net loss of $15.8 million, or $0.21 per share, compared to $13.2 million, or $0.17 per share, in Q3 2021. The company ended the quarter with $155 million in cash, supporting ongoing clinical trials for VK2809, VK2735, and VK0214, with data expected in 2023. The Phase 2b VOYAGE study for VK2809 is on track for Q4 2022 enrollment completion. Increased R&D and G&A expenses were noted, affecting the overall financial performance.
Viking Therapeutics (NASDAQ: VKTX) announced the release of its third-quarter 2022 financial results on October 26, 2022, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates. The company's pipeline includes VK2809, in Phase 2b for NASH, and VK2735, in Phase 1 for metabolic disorders, showcasing ongoing innovation in therapies targeting metabolic and endocrine conditions.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in two investor conferences from September 12-14, 2022. At the H.C. Wainwright 24th Annual Global Investment Conference, Dr. Lian will deliver a presentation on September 14 at 12:30 PM Eastern, with a hybrid format available. Additionally, Viking management will engage in 1-on-1 meetings at the Morgan Stanley 20th Annual Global Healthcare Conference during the same dates, held at the Sheraton New York Hotel. Webcasts of the presentations will be accessible via the Viking Therapeutics website.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
